ALTIMMUNE, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
ALTIMMUNE, INC. (ALT) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$667.46 thousand for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-15.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-15
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$667.46K, a 566.36% decline year-over-year.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was -$28.74K.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was -$15.43K.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was $13.63M.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $13.73M.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$220.57K.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$78.91K.
- ALTIMMUNE, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$84.27K.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2018-03-31 | -$667.46K 10-Q · filed 2018-05-15 | -$696.20K derived: sum of 2 quarters · filed 2018-05-15 | -$711.63K derived: sum of 3 quarters · filed 2018-05-15 | $12.92M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-12-31 | -$28.74K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$44.17K derived: sum of 2 quarters · filed 2018-04-02 | $13.58M derived: sum of 3 quarters · filed 2018-04-02 | $13.73M 10-K · filed 2018-04-02 | ||||
| 2017-09-30 | -$15.43K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $13.61M derived: sum of 2 quarters · filed 2017-11-09 | $13.75M 10-Q · filed 2017-11-09 | $13.71M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-06-30 | $13.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $13.77M 10-Q · filed 2017-08-14 | $13.73M derived: sum of 3 quarters · filed 2018-05-15 | $13.61M derived: sum of 4 quarters · filed 2018-05-15 | ||||
| 2017-03-31 | $143.12K 10-Q · filed 2018-05-15 | $66.80M 10-Q · filed 2017-05-03 | $101.90K derived: sum of 2 quarters · filed 2018-05-15 | -$17.55K derived: sum of 3 quarters · filed 2018-05-15 | -$77.30K derived: sum of 4 quarters · filed 2018-05-15 | |||
| 2016-12-31 | -$41.22K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-02 | -$160.67K derived: sum of 2 quarters · filed 2018-04-02 | -$220.42K derived: sum of 3 quarters · filed 2018-04-02 | -$220.57K 10-K · filed 2018-04-02 | -$66.88M 10-K · filed 2017-03-14 | |||
| 2016-09-30 | -$119.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$179.20K derived: sum of 2 quarters · filed 2017-11-09 | -$179.35K 10-Q · filed 2017-11-09 | -$66.88M 10-Q · filed 2016-11-04 | -$197.58K derived: sum of 4 quarters · filed 2017-11-09 | |||
| 2016-06-30 | -$59.75K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$59.90K 10-Q · filed 2017-08-14 | -$27.45K 10-Q · filed 2016-08-04 | -$78.13K derived: sum of 3 quarters · filed 2017-08-14 | -$90.13K derived: sum of 4 quarters · filed 2017-08-14 | |||
| 2016-03-31 | -$150.00 10-Q · filed 2017-05-03 | -$18.38K derived: sum of 2 quarters · filed 2017-05-03 | -$30.38K derived: sum of 3 quarters · filed 2017-05-03 | -$51.30K derived: sum of 4 quarters · filed 2017-05-03 | ||||
| 2015-12-31 | -$18.23K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$30.23K derived: sum of 2 quarters · filed 2017-03-14 | -$51.16K derived: sum of 3 quarters · filed 2017-03-14 | -$78.91K 10-K · filed 2017-03-14 | ||||
| 2015-09-30 | -$12.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-04 | -$32.92K derived: sum of 2 quarters · filed 2016-11-04 | -$60.68K 10-Q · filed 2016-11-04 | -$60.68K derived: sum of 4 quarters · filed 2017-03-14 | ||||
| 2015-06-30 | -$20.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$48.68K 10-Q · filed 2016-08-04 | -$48.68K derived: sum of 3 quarters · filed 2017-03-14 | |||||
| 2015-03-31 | -$27.75K 10-Q · filed 2016-05-09 | -$27.75K derived: sum of 2 quarters · filed 2017-03-14 | ||||||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | -$84.27K 10-K · filed 2017-03-14 | ||||||
| 2014-09-30 | -$84.27K 10-Q · filed 2015-11-06 | |||||||
| 2013-12-31 | -$81.08K 10-K · filed 2016-03-11 | |||||||
| 2012-12-31 | $67.40K 10-K · filed 2015-03-11 | |||||||
| 2011-12-31 | $1.69M 10-K · filed 2014-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |